

ALung Launched Hemolung RAS in France



ALung Technologies, Inc., a leading developer of innovative respiratory assist devices, announced on September 12, 2013, the launch of its Hemolung Respiratory Assist System (RAS) in France. ALung showcased the Hemolung RAS at the 2013 National Congress of the French Society of Anesthesia and Intensive Care (SFAR) in Paris. ALung's entry into the French market is led by Jean-Michel Dutois, a seasoned medical device executive who recently joined ALung as Country Manager for France.

The Hemolung RAS removes carbon dioxide and delivers oxygen directly to the blood, allowing a patient's lungs to rest and heal in cases of acute respiratory failure. The device received CE Mark approval in February 2013, and is initially being made available to a select group of hospitals participating in ALung's Hemolung Reference Center Program. "I am very pleased to see this exciting new technology be made available in France," said Prof. Alain Combes from La Pitié-Salpétrière ICU in Paris, who is participating in the Hemolung Reference Center Program. "In my opinion, there is a lot of promise for extracorporeal lung support devices like the Hemolung RAS to facilitate better outcomes in cases of acute respiratory failure."

ALung has established a direct sales and support organization in France. "I am very excited to have the opportunity to launch the Hemolung RAS. We have already received tremendous support from local physicians who agree that minimally invasive extracorporeal carbon dioxide removal is an ideal solution for those suffering from respiratory failure," said Jean-Michel Dutois, ALung's Country Manager for France.

Source: ALung Inc.

Published on : Thu, 19 Sep 2013